Questionnaire on the clinical praxis of percutaneous endoscopic gastrostomy insertion in patients with autosomal recessive polycystic kidney disease (ARPKD)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011012

Enrollment

200

Registered

2016-11-21

Start date

2017-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Q61.1

Interventions

Group 1: Conduction of a webbased, anonymous questionnaire of attending physicians of European pediatric nephrology and gastroenterology centers questioning the common practice regarding PEG implantat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The interviewed colleagues work at centers for pediatric nephrolgy or pediatric hepatology in Europe and diagnosed ARPKD due to clinical criteria in the patients. The data of ARPKD patients are questioned in an anonymous and retrospective manner.

Exclusion criteria

Exclusion criteria: not willing to participate

Design outcomes

Primary

Measure	Time frame
It is the aim of the questionnaire to collect data regarding the current practice of PEG (percutaneous endoscopic gastrostomy) implantations in ARPKD (autosomal recessive polycystic kidney disease) patients in European pediatric centers and the experiences obtained. Benefit and risks of the intervention are evaluated in a retrospective manner in order to create first evidence regarding this important therapy in patients suffering from this serious disease of early childhood.	—

Measure

Time frame

It is the aim of the questionnaire to collect data regarding the current practice of PEG (percutaneous endoscopic gastrostomy) implantations in ARPKD (autosomal recessive polycystic kidney disease) patients in European pediatric centers and the experiences obtained. Benefit and risks of the intervention are evaluated in a retrospective manner in order to create first evidence regarding this important therapy in patients suffering from this serious disease of early childhood.

—

Countries

Belgium, Czechia, France, Germany, Italy, Poland, Portugal, Spain, Turkey, United Kingdom

Contacts

Public ContactKathrin Burgmaier

Klinik für Kinder- und JugendmedizinUniklinik Köln

kathrin.burgmaier@uk-koeln.de0221/478-4359

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026